{"links":{"html":"https://www.erudio.com/reports/mk-3475-975-keynote-975-nct04210115","json":"https://www.erudio.com/reports/mk-3475-975-keynote-975-nct04210115.json","markdown":"https://www.erudio.com/reports/mk-3475-975-keynote-975-nct04210115.md","mcp":{"server":"https://mcp.erudio.com/mcp","tool":"get_report_card","arguments":{"slug":"mk-3475-975-keynote-975-04210115"}},"request":"https://www.erudio.com/contact?report=mk-3475-975-keynote-975-04210115"},"offer":{"cited_commentary_sources":16,"verified_hcp_statements":180,"currency":"USD","delivery":{"checkout":"online","current_edition":"Emailed as soon as payment clears: downloads, a license key and a prompt that connects your AI agent through Erudio MCP. One key per email address holds every report bought with it.","refresh":"A purchase starts a check for new commentary. A new edition, if one results, is sent to the buyer at no charge."},"identities":{"adds":"Verified IDs for the clinicians in the report, led by the NPI, so a Medical Affairs team can connect the report's voices to the expert and insight records it keeps by NPI. For scientific and insight use inside the organization, not for promotional targeting or outreach. Every report already names and describes its speakers.","available_with":"12-month updates","cap_usd":1250,"identity_verified_people":19,"optional":true,"price_per_verified_person_usd":15,"price_usd":285,"product":"updates-12-identities","terms":"Priced on the identity-verified people in the edition at purchase; people verified later in the term come at no charge."},"one_off_usd":1250,"purchase":{"agents":{"free_mcp":"https://mcp.erudio.com/free","keys":"One license key holds every report: get_order returns it once paid (store it as a secret), send it as licence_key with every later create_order so new reports join it. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST /api/keys/recover) with the buyer's email sends it again.","mcp_tools":["create_order","get_order","recover_key"],"order_endpoint":"https://www.erudio.com/api/orders","order_request":{"buyer_email":"name@company.com","idempotency_key":"optional, one per purchase","licence_key":"optional: your key from an earlier purchase","organization":"optional","product":["edition","updates-3","updates-6","updates-12","updates-12-identities"],"report":"mk-3475-975-keynote-975-nct04210115"},"steps":"Create the order (with licence_key if you hold one) and show checkout_url to your person to pay by card. If the order also returns pay_url, you can pay it yourself instead: POST pay_url answers 402 Payment Required with MPP or x402 offers for your payment client. Once paid, status_url (or get_order) returns the license key, the MCP setup and downloads."},"contact":{"email":"hello@erudio.com","form":"https://www.erudio.com/contact?report=mk-3475-975-keynote-975-04210115","people":"Audun Utengen and Tom Lee, the founders","use_for":"Questions, invoices, purchase orders"},"methods":["card (Stripe Checkout)"],"people":"https://www.erudio.com/reports/mk-3475-975-keynote-975-nct04210115","renewal":"Subscriptions are prepaid and do not renew automatically.","upgrades":"What the buyer already paid on this trial counts toward a longer plan: a one-off edition within 30 days, or an active plan at any time in its term. The buyer pays the difference; an upgraded plan keeps its original start, and an upgraded one-off starts the plan on payment. Order the longer product with create_order and the buyer's licence_key (or on the report page with the buyer's email); the quote shows the credit.","terms":"https://www.erudio.com/terms"},"size":"standard","size_rule":"Standard: 151–300 verified statements","updates_usd":{"3_months":2200,"6_months":3100,"12_months":4400},"volume_discounts":[{"min_subscribed_trials":10,"percent_off_updates":25},{"min_subscribed_trials":5,"percent_off_updates":15}]},"publication_state":"public","record":{"change":{"changed_finding_ids":{"reason":"No changed finding IDs recorded.","status":"none"},"last_checked_at":"2026-10-18T22:07:59.892613Z","notify_subscribers":false,"status":"new","summary":{"reason":"Initial accepted edition has no weekly change log.","status":"not_applicable"}},"contents":{"aspect_coverage":{"assessment_incomplete":0,"discussed":14,"no_commentary_found":2},"aspects":[{"claim_count":3,"coverage":"discussed","id":"T1","registry_field":"outcomesModule.primaryOutcomes[0]","source_count":2,"title":"Primary endpoint: Event-free Survival (EFS)"},{"claim_count":3,"coverage":"discussed","id":"T2","registry_field":"outcomesModule.primaryOutcomes[1]","source_count":2,"title":"Primary endpoint: Overall Survival (OS)"},{"claim_count":0,"coverage":"no_commentary_found","id":"T3","registry_field":"outcomesModule.secondaryOutcomes[0]","source_count":0,"title":"Secondary endpoint: Number of participants with an adverse event (AE)"},{"claim_count":0,"coverage":"no_commentary_found","id":"T4","registry_field":"outcomesModule.secondaryOutcomes[1]","source_count":0,"title":"Secondary endpoint: Number of participants discontinuing study treatment due to an adverse event (AE)"},{"claim_count":21,"coverage":"discussed","id":"T5","registry_field":"conditionsModule","source_count":9,"title":"Population and setting"},{"claim_count":6,"coverage":"discussed","id":"T6","registry_field":"armsInterventionsModule.armGroups","source_count":5,"title":"The comparison"},{"claim_count":9,"coverage":"discussed","id":"T7","registry_field":"outcomesModule","source_count":2,"title":"Safety and tolerability"},{"claim_count":3,"coverage":"discussed","id":"T8","registry_field":"designModule","source_count":2,"title":"Design and conduct"},{"claim_count":17,"coverage":"discussed","id":"A1","source_count":3,"title":"Residual disease without surgery: additional systemic therapy, withholding and selective exceptions"},{"claim_count":21,"coverage":"discussed","id":"A2","source_count":3,"title":"Staging, airway invasion, referral and multidisciplinary suitability"},{"claim_count":35,"coverage":"discussed","id":"A3","source_count":1,"title":"CPS measurement, reporting and confidence near treatment thresholds"},{"claim_count":23,"coverage":"discussed","id":"A4","source_count":6,"title":"Who still receives dCRT amid perioperative and surgical alternatives?"},{"claim_count":15,"coverage":"discussed","id":"A5","source_count":2,"title":"Surgery omission, organ preservation and salvage-surgery trade-offs"},{"claim_count":18,"coverage":"discussed","id":"A6","source_count":3,"title":"Complete-response assessment and surveillance for nonoperative management"},{"claim_count":27,"coverage":"discussed","id":"A7","source_count":8,"title":"Research priorities, meaningful endpoints, feasibility and expectations"},{"claim_count":11,"coverage":"discussed","id":"A8","source_count":2,"title":"Radiation-dose debate and alternative chemoradiation backbones"}],"counts":{"cited_sources":17,"claims_by_expression_type":{"comparison":11,"experience":16,"interpretation":15,"opinion":34,"primary_context":2,"question":20,"restatement":13,"uncertainty":18,"unspecified":51},"claims_by_kind":{"attributed_opinion":32,"interpretation":4,"limitation":5,"protocol_statement":1,"source_observation":138},"clinician_statements":80,"evidence_units":115,"findings":11,"people_cited":24,"people_identity_verified":19,"people_total":25,"screened_sources":22,"verified_claims":180},"depth":"standard","findings_index":[{"id":"F1","structure":{"claims":6,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":4,"views":2},"has_counterview":false,"limitations":2,"links":{"context":0,"support":7},"ma_question":true,"named_voices":4,"passages":6,"sources":5,"sources_by_kind":{"commentary":3,"media":1,"registry":1}},"title":"Negative EFS announcements are consequential, but are not a complete results assessment"},{"id":"F2","structure":{"claims":17,"claims_by_group":{"comparisons":0,"experience":2,"questions":5,"restated":5,"views":5},"has_counterview":false,"limitations":2,"links":{"context":0,"support":23},"ma_question":true,"named_voices":2,"passages":9,"sources":3,"sources_by_kind":{"media":3}},"title":"Routine post-chemoradiation nivolumab without surgery is questioned, with selective exceptions"},{"id":"F3","structure":{"claims":15,"claims_by_group":{"comparisons":2,"experience":0,"questions":5,"restated":5,"views":3},"has_counterview":true,"limitations":3,"links":{"context":0,"support":21},"ma_question":true,"named_voices":4,"passages":8,"sources":7,"sources_by_kind":{"media":7}},"title":"Histology drives expectations and challenges interpretation of pooled populations"},{"id":"F4","structure":{"claims":21,"claims_by_group":{"comparisons":1,"experience":4,"questions":3,"restated":7,"views":6},"has_counterview":false,"limitations":2,"links":{"context":3,"support":23},"ma_question":true,"named_voices":3,"passages":11,"sources":3,"sources_by_kind":{"media":3}},"title":"Staging errors can change the entire definitive-treatment decision"},{"id":"F5","structure":{"claims":36,"claims_by_group":{"comparisons":2,"experience":3,"questions":2,"restated":26,"views":3},"has_counterview":true,"limitations":2,"links":{"context":1,"support":78},"ma_question":true,"named_voices":2,"passages":17,"sources":2,"sources_by_kind":{"media":1,"registry":1}},"title":"PD-L1 scoring concerns complicate confidence near treatment thresholds"},{"id":"F6","structure":{"claims":23,"claims_by_group":{"comparisons":3,"experience":1,"questions":5,"restated":6,"views":8},"has_counterview":true,"limitations":2,"links":{"context":0,"support":26},"ma_question":true,"named_voices":5,"passages":13,"sources":6,"sources_by_kind":{"commentary":1,"media":5}},"title":"Perioperative advances narrow—but do not eliminate—the perceived role of dCRT"},{"id":"F7","structure":{"claims":14,"claims_by_group":{"comparisons":1,"experience":0,"questions":5,"restated":0,"views":8},"has_counterview":true,"limitations":2,"links":{"context":0,"support":15},"ma_question":true,"named_voices":6,"passages":14,"sources":1,"sources_by_kind":{"commentary":1}},"title":"Organ preservation exposes a substantive dispute over surgery's value and burden"},{"id":"F8","structure":{"claims":18,"claims_by_group":{"comparisons":0,"experience":6,"questions":6,"restated":2,"views":4},"has_counterview":true,"limitations":2,"links":{"context":1,"support":19},"ma_question":true,"named_voices":7,"passages":16,"sources":3,"sources_by_kind":{"commentary":2,"media":1}},"title":"Nonoperative management depends on uncertain selection and nonuniform surveillance"},{"id":"F9","structure":{"claims":11,"claims_by_group":{"comparisons":1,"experience":0,"questions":4,"restated":2,"views":4},"has_counterview":true,"limitations":2,"links":{"context":0,"support":12},"ma_question":true,"named_voices":4,"passages":9,"sources":3,"sources_by_kind":{"commentary":1,"media":1,"registry":1}},"title":"Concurrent timing, chemotherapy restrictions and radiation dose shape interpretability"},{"id":"F10","structure":{"claims":19,"claims_by_group":{"comparisons":0,"experience":2,"questions":5,"restated":5,"views":7},"has_counterview":false,"limitations":3,"links":{"context":0,"support":20},"ma_question":true,"named_voices":10,"passages":16,"sources":4,"sources_by_kind":{"commentary":2,"media":2}},"title":"Research enthusiasm is qualified by endpoint priorities, feasibility and uncertain mechanisms of benefit"},{"id":"F11","structure":{"claims":8,"claims_by_group":{"comparisons":1,"experience":0,"questions":0,"restated":6,"views":1},"has_counterview":false,"limitations":2,"links":{"context":1,"support":8},"ma_question":true,"named_voices":0,"passages":3,"sources":1,"sources_by_kind":{"media":1}},"title":"Immune-toxicity vigilance qualifies enthusiasm for treatment intensification"}],"medical_affairs_question":"How should the announced lack of EFS improvement be communicated without implying known OS, subgroup or safety conclusions?","sections":{"analysis":[{"id":"section-1","level":2,"title":"Negative EFS reports do not settle every immunotherapy decision"},{"id":"section-2","level":2,"title":"Withholding routine post-CRT treatment coexists with selective extrapolation"},{"id":"section-3","level":2,"title":"Histology separates systemic hope from local-response evidence"},{"id":"section-4","level":2,"title":"Staging determines whether the definitive-treatment question applies"},{"id":"section-5","level":2,"title":"CPS uncertainty is a clinical communication issue, not proof of trial assay failure"},{"id":"section-6","level":2,"title":"Perioperative advances leave a narrower but important dCRT population"},{"id":"section-7","level":2,"title":"Organ preservation raises a real dispute about surgery, not a settled replacement strategy"},{"id":"section-8","level":2,"title":"Observation requires selection tools and a follow-up strategy"},{"id":"section-9","level":2,"title":"Backbone, dose and sequencing criticisms should remain separate"},{"id":"section-10","level":2,"title":"Research proposals compete on endpoints and feasibility"},{"id":"section-11","level":2,"title":"Immune-toxicity vigilance limits uncomplicated intensification narratives"},{"id":"section-12","level":2,"title":"Scope and coverage"}],"executive_summary":{"reason":"Reviewed narrative has no headings.","status":"unavailable"}},"study_design":"interventional, randomized, parallel, phase3","trial_dimensions":[{"findings":[{"id":"F1","shared_claims":3}],"id":"T1","label":"Primary endpoint: Event-free Survival (EFS)"},{"findings":[{"id":"F3","shared_claims":2},{"id":"F10","shared_claims":1}],"id":"T2","label":"Primary endpoint: Overall Survival (OS)"},{"findings":[],"id":"T3","label":"Secondary endpoint: Number of participants with an adverse event (AE)"},{"findings":[],"id":"T4","label":"Secondary endpoint: Number of participants discontinuing study treatment due to an adverse event (AE)"},{"findings":[{"id":"F3","shared_claims":10},{"id":"F4","shared_claims":5},{"id":"F6","shared_claims":6}],"id":"T5","label":"Population and setting"},{"findings":[{"id":"F3","shared_claims":3},{"id":"F9","shared_claims":2}],"id":"T6","label":"The comparison"},{"findings":[{"id":"F9","shared_claims":1},{"id":"F11","shared_claims":8}],"id":"T7","label":"Safety and tolerability"},{"findings":[{"id":"F3","shared_claims":1},{"id":"F9","shared_claims":2}],"id":"T8","label":"Design and conduct"}]},"identity":{"accepted_at":"2026-10-18T22:07:59.892613Z","edition_number":1,"previous_run_id":{"reason":"First accepted catalog edition.","status":"not_applicable"},"previous_version":{"reason":"First accepted catalog edition.","status":"not_applicable"},"product_contract":"hcp-commentary-1","published_at":"2026-10-18T23:11:43Z","record_hash":"2bbc053d01f83d761a0ad89e245e4e9d73ef4fb1f4d7db64f914330b538c8fe6","release_hash":"4f7b7e8fa4f3db92ae461ad654665f6ebb48123a7afd2165ee0a42ca692b6504","report_id":"erudio-nct04210115","run_id":"9a4b34a1-29e6-43a4-8ff4-8428350dc201","schema_version":"5.0","slug":"mk-3475-975-keynote-975-04210115","version":"1.0.0","version_reason":"initial"},"offer":{"bundle_eligible":{"reason":"Owner has not set bundle_eligible.","status":"not_set"},"license_ref":{"reason":"Owner has not set license_ref.","status":"not_set"},"request_route":{"reason":"Owner has not set request_route.","status":"not_set"},"single_edition":{"reason":"Owner has not set single_edition.","status":"not_set"},"updates":{"reason":"Owner has not set updates.","status":"not_set"}},"preview":{"abstract":"KEYNOTE-975 asks whether adding pembrolizumab to definitive chemoradiation improves outcomes for patients with esophageal cancer treated without planned surgery. Clinicians discuss survival endpoints, residual disease, treatment sequencing, histology, PD-L1 testing, staging and multidisciplinary referral, and immune toxicity. Other topics include chemotherapy choices, radiation dose, perioperative alternatives, organ preservation, response assessment, surveillance and evidence needed to change care. The trial’s main results are expected at ESMO 2026; this report reflects commentary before that presentation.","meta_description":"22 sources screened · 180 verified statements (80 from speakers with a confirmed clinical role) from 17 sources · 11 findings. Updated Oct 18, 2026.","person_names_policy":"role_only","sample_findings":[{"cited_claim_ids":["claim-353186bdacd479edacc5"],"id":"F2","paraphrase":"A podcast moderator asked whether adjuvant nivolumab should be offered after neoadjuvant chemoradiation when a patient with initially resectable disease declines surgery or is judged surgically ineligible.","publication_caveats":["The drug and timing differ from KEYNOTE-975: this question concerns nivolumab after neoadjuvant chemoradiation, rather than pembrolizumab given with definitive chemoradiation."],"source_channel":"podcast","source_date":"2024-02-07","title":"Routine post-chemoradiation nivolumab without surgery is questioned, with selective exceptions"},{"cited_claim_ids":["claim-4a62817ffdd4734beadb","claim-fe949b57247f700d0940","claim-061d05acce0e4a7d739c"],"id":"F5","paraphrase":"A speaker in a YouTube discussion asked which tissue to use for PD-L1 CPS testing and whether testing should precede or follow therapy. Further questions addressed study-specific versus routine scorer training and when treatment could proceed without PD-L1 staining.","publication_caveats":["This was a general gastroesophageal biomarker discussion from 2022, not an evaluation of assay performance in KEYNOTE-975.","Local reporting thresholds discussed reflected practice at that time, not KEYNOTE-975 selection criteria."],"source_channel":"youtube","source_date":"2022-06-22","title":"PD-L1 scoring concerns complicate confidence near treatment thresholds"}]},"publication":{"approved_at":"2026-10-18T23:11:43Z","approved_by":"Erudio publisher","corrections":[],"rights_status":"cleared: short attributed excerpts with link-out; no-derivatives sources suppressed; role-only names in previews","state":"public"},"schema_id":"erudio.catalog_record","schema_version":"2.1","scope_and_limits":{"commentary_scope":{"basis":"Only the sources used in this report; not all HCPs or all public discussion.","has_known_gaps":true,"source_count":22},"does_not":["judge efficacy","estimate HCP prevalence or consensus","give treatment advice"],"known_gaps":["Discussion that does not name the trial may be missing from this edition.","For 1 recording, a transcript separated by speaker was not available, so quotes come from the original automatic transcript and may lack speaker labels.","Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.","Out of scope: 18 passages in the reviewed sources discuss other trials or topics outside this report's scope; they are not part of this edition.","79 statements in the sources reviewed for this edition discuss other treatment settings or topics unrelated to this trial's question and are not included.","Further source limits apply, so some matching discussion may be missing.","The sources reviewed are not a representative sample of HCP opinion, and multiple formats of one discussion do not represent independent agreement.","Some potentially relevant posts and a video were unavailable to read. Parts of several long discussions were not completely assessed, so additional relevant opinions may be missing.","Several treatment, histology and safety comments cannot be reliably assigned to a named speaker. A program roster, institutional reference or professional identifier does not resolve that uncertainty.","Professional information is incomplete for some named contributors. Daisuke Kotani's and Megan Lenihan's clinical roles are not confirmed for this edition; names and source attribution do not verify credentials.","The negative EFS statements relay sponsor announcements. No KEYNOTE-975 results publication, quantitative efficacy analysis, detailed subgroup analysis or comparative safety analysis is among the sources reviewed.","Earlier anticipatory comments and later announcement reactions come from different dates and contexts. Their sequence does not establish a change of mind or direct disagreement over detailed results.","Some transcript wording is unclear, including an overexpression qualifier in the adenocarcinoma discussion; the initial organ-preservation proposal is truncated.","Cross-disease analogies, other-study response figures, institutional experience and anecdotal tolerability observations are not KEYNOTE-975 outcomes.","No full protocol document or complete regulatory evidence is available here. Descriptions of prescribing labels and local treatment standards remain the contributors' accounts.","General CPS-scoring concerns do not establish inaccurate testing in KEYNOTE-975, and local historical reporting thresholds must not be substituted for trial criteria."]},"sources":{"cited_sources":{"by_channel":{"other":0,"podcast":4,"publication":0,"registry":1,"regulatory":0,"x_thread":7,"x_video":0,"youtube":5},"by_evidence_role":{"commentary":16,"methods":1},"count":17,"evidence_window":{"end":"2026-10-16","start":"2022-06-22"},"retrieval_snapshot":"2026-10-18T11:06:10.058477Z","timeline":[{"count":1,"week":"2022-W25"},{"count":1,"week":"2022-W51"},{"count":1,"week":"2023-W12"},{"count":1,"week":"2023-W13"},{"count":1,"week":"2023-W25"},{"count":1,"week":"2023-W26"},{"count":1,"week":"2023-W42"},{"count":1,"week":"2024-W06"},{"count":1,"week":"2024-W28"},{"count":1,"week":"2024-W31"},{"count":1,"week":"2024-W47"},{"count":2,"week":"2026-W18"},{"count":1,"week":"2026-W20"},{"count":3,"week":"2026-W40"},{"count":1,"week":"2026-W42"}],"undated_sources":1},"quote_policies":[{"id":"clinicaltrials:NCT04210115:methods","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT04210115:context","quote_policy":"short_quote_link_out"},{"id":"pubmed:33533655","quote_policy":"no_derivatives"},{"id":"openfda:097d166f-b73b-41d3-9b37-7653cd2a0c41:20260731","quote_policy":"short_quote_link_out"},{"id":"openfda:508496cb-3441-46b3-a4fe-e0d440e6adc6:20260624","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:362b41","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:7fe157","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:91b7d8","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:f42d90","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1377048372725624833:39a28401-d37b-4299-bbff-70898f9f6d9a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1502071881855344650:6864e321-af63-4dbe-8063-688d3b9a1c9e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1537223665745543169:153baa26-d7d8-4745-9622-e2d239c00f05","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1638179910371135488:c8b62ba3-9115-4c56-805b-b401b393a8cb","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1672245397681496065:2401d42b-7792-4efb-b487-d8cb8c7dd3ee","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1714417031435493840:0c8e02a7-6b1a-41f5-a221-de0c3a0adf1c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2049824836093125057:e45e72b3-b3d1-4f13-bdf0-d4ad32128831","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2050241911160475759:208350ad-76ef-4ef7-a422-eb6edd21e103","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2102432534395306414:b08afc32-8f0f-439e-8164-f5086c091554","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2104356268454686951:b359d6e5-399d-40a5-8f52-05cb4f96eb63","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2105990928217334044:c005e9b7-687f-4ccb-8337-1162e1a8d6a5","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2110607787776745536:d02580f1-82d4-40a3-b92b-82849085c040","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2111079668140900657:b2f67a8b-827c-42cd-a517-d6ee60e51885","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:BZBokhX_eW4","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:Ft-ih9xbsxA","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:NiedxmQiua4","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:U7eFmld9eVg","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:ZnOpPCU6VMw","quote_policy":"short_quote_link_out"}],"screened_sources":{"by_channel":{"other":0,"podcast":4,"publication":0,"registry":0,"regulatory":0,"x_thread":13,"x_video":0,"youtube":5},"by_evidence_role":{"commentary":22},"count":22,"evidence_window":{"end":"2026-10-16","start":"2021-03-31"},"retrieval_snapshot":"2026-10-18T11:06:10.058477Z","timeline":[{"count":1,"week":"2021-W13"},{"count":1,"week":"2022-W10"},{"count":1,"week":"2022-W24"},{"count":1,"week":"2022-W25"},{"count":1,"week":"2022-W51"},{"count":1,"week":"2023-W12"},{"count":1,"week":"2023-W13"},{"count":1,"week":"2023-W25"},{"count":1,"week":"2023-W26"},{"count":1,"week":"2023-W42"},{"count":1,"week":"2024-W06"},{"count":1,"week":"2024-W28"},{"count":1,"week":"2024-W31"},{"count":1,"week":"2024-W47"},{"count":2,"week":"2026-W18"},{"count":1,"week":"2026-W20"},{"count":2,"week":"2026-W39"},{"count":3,"week":"2026-W40"},{"count":2,"week":"2026-W42"}],"undated_sources":0}},"taxonomy":{"biomarkers":{"reason":"No structured, checked-in biomarker mapping for this trial.","status":"unmapped"},"conferences":{"reason":"No conferences in source metadata.","status":"none"},"drugs":[{"brand_names":["Keytruda"],"label":"pembrolizumab","slug":"pembrolizumab"},{"brand_names":["Platinol"],"label":"cisplatin","slug":"cisplatin"},{"brand_names":["Adrucil","Favlyxa"],"label":"fluorouracil","slug":"fluorouracil"},{"brand_names":["Vykoura","Wellcovorin"],"label":"leucovorin","slug":"leucovorin"},{"reason":"Unmapped registry intervention: levoleucovorin","status":"unmapped"},{"brand_names":["Eloxatin"],"label":"oxaliplatin","slug":"oxaliplatin"}],"indications":[{"reason":"Unmapped registry condition: Esophageal Squamous Cell Carcinoma (ESCC)","status":"unmapped"},{"reason":"Unmapped registry condition: Gastroesophageal Junction Carcinoma (GEJC)","status":"unmapped"},{"reason":"Unmapped registry condition: Esophageal Adenocarcinoma (EAC)","status":"unmapped"}],"line_of_therapy":{"reason":"No structured, checked-in line-of-therapy mapping for this trial.","status":"unmapped"},"therapeutic_area":{"reason":"Conditions lack a therapeutic-area mapping.","status":"unmapped"}},"trial":{"acronym":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"aliases":["Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)","A Randomized, Double-blind, Placebo-controlled Phase 3 Trial of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Receiving Concurrent Definitive Chemoradiotherapy (KEYNOTE 975)"],"brief_title":"Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)","collaborators":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"conditions":["Esophageal Squamous Cell Carcinoma (ESCC)","Gastroesophageal Junction Carcinoma (GEJC)","Esophageal Adenocarcinoma (EAC)"],"enrollment":{"count":703,"type":"ACTUAL"},"interventions":[{"name":"pembrolizumab","synonyms":["MK-3475","KEYTRUDA®"],"type":"BIOLOGICAL"},{"name":"placebo","synonyms":["Normal saline solution"],"type":"DRUG"},{"name":"cisplatin","synonyms":["PLATINOL®"],"type":"DRUG"},{"name":"5-FU","synonyms":["ADRUCIL®"],"type":"DRUG"},{"name":"radiotherapy","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"RADIATION"},{"name":"leucovorin","synonyms":["calcium folinate","folinic acid"],"type":"DRUG"},{"name":"levoleucovorin","synonyms":["FUSILEV®","calcium levofolinate","levofolinic acid"],"type":"DRUG"},{"name":"oxaliplatin","synonyms":["ELOXATIN®"],"type":"DRUG"}],"nct_id":"NCT04210115","official_title":"A Randomized, Double-blind, Placebo-controlled Phase 3 Trial of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Receiving Concurrent Definitive Chemoradiotherapy (KEYNOTE 975)","overall_status":"COMPLETED","phase":["PHASE3"],"primary_completion_date":{"date":"2026-01-21","type":"ACTUAL"},"primary_endpoints":[{"description":"EFS is defined as the time from randomization to an event defined as local, regional, or distant radiological recurrence as assessed by the investigator; clinical recurrence as assessed by the investigator with histopathologic confirmation (in the absence of radiological disease recurrence by investigator assessment); or death from any cause, whichever occurs first.","measure":"Event-free Survival (EFS)","timeFrame":"Up to ~60 months"},{"description":"OS is defined as the time from randomization to death from any cause.","measure":"Overall Survival (OS)","timeFrame":"Up to ~72 months"}],"registry_last_updated":"2026-07-22","registry_url":"https://clinicaltrials.gov/study/NCT04210115","short_name":"MK-3475-975/KEYNOTE-975","short_name_basis":"registry_title","sponsor":"Merck Sharp & Dohme LLC","start_date":{"date":"2020-02-28","type":"ACTUAL"},"study_design":"interventional, randomized, parallel, phase3","study_ids":[{"id":"3475-975","type":"sponsor_study_id"},{"domain":"MSD","id":"MK-3475-975","type":"other"},{"domain":"MSD","id":"KEYNOTE-975","type":"other"},{"domain":"PHRR","id":"PHRR200210-002490","type":"registry"},{"domain":"Japic-CTI","id":"205261","type":"registry"},{"domain":"EU CT","id":"2022-501531-16-00","type":"registry"},{"domain":"UTN","id":"U1111-1281-0822","type":"registry"},{"id":"2019-002006-51","type":"eudract_number"}],"study_type":"INTERVENTIONAL"}}}